Giovanna Gentile

Prof. Giovanna Gentile

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MBMarina Borro
Marina Borro
Paolo Di GirolamoPaolo Di Girolamo
Paolo Di Girolamo
GGGiovanna Gentile
Giovanna Gentile
OLottavia de luca
ottavia de luca
RPRobert Preissner
Robert Preissner
MSMaurizio Simmaco
Maurizio Simmaco
The COVID-19/SARS-CoV-2 pandemic struck health, social and economic systems worldwide, and represents an open challenge for scientists —coping with the high inter-individual variability of COVID-19, and for policy makers —coping with the responsibility to understand environmental factors affecting its severity across different geographical areas. Air pollution has been warned of as a modifiable factor contributing to differential SARS-CoV-2 spread but the biological mechanisms underlying the phenomenon are still unknown. Air quality and COVID-19 epidemiological data from 110 Italian provinces were studied by correlation analysis, to evaluate the association between particulate matter (PM)2.5 concentrations and incidence, mortality rate and case fatality risk of COVID-19 in the period 20 February–31 March 2020. Bioinformatic analysis of the DNA sequence encoding the SARS-CoV-2 cell receptor angiotensin-converting enzyme 2 (ACE-2) was performed to identify consensus motifs for transcription factors mediating cellular response to pollutant insult. Positive correlations between PM2.5 levels and the incidence (r = 0.67, p < 0.0001), the mortality rate (r = 0.65, p < 0.0001) and the case fatality rate (r = 0.7, p < 0.0001) of COVID-19 were found. The bioinformatic analysis of the ACE-2 gene identified nine putative consensus motifs for the aryl hydrocarbon receptor (AHR). Our results confirm the supposed link between air pollution and the rate and outcome of SARS-CoV-2 infection and support the hypothesis that pollution-induced over-expression of ACE-2 on human airways may favor SARS-CoV-2 infectivity.

1 March 2007 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PFPietro Francia
Pietro Francia
ASAdriano Salvati
Adriano Salvati
CBcristina balla
cristina balla
PPPaola De Paolis
Paola De Paolis
EPErika Pagannone
Erika Pagannone
MVMassimo Volpe
Massimo Volpe
Background: Cardiac resynchronization therapy (CRT) has been introduced to treat drug refractory chronic heart failure (CHF). Apelin, the endogenous ligand of the APJ receptor, is under evaluation for its potential role in human CHF pathophysiology. This study aims to assess whether biventricular pacing affects plasma apelin levels in patients with severe CHF. Methods and results: Fourteen patients (9 men, 5 women, mean age 68±13years) undergoing biventricular pace-maker/ICD implantation were studied. Patients underwent baseline clinical and echocardiographic evaluation, and assessment of plasma apelin and NT-proBNP levels. The evaluation was repeated 48h and 9±2months after device implantation to assess the acute and chronic effects of CRT on apelin and NT-proBNP levels. Eight healthy age- and sex-matched subjects served as controls. In CHF patients, baseline apelin levels were reduced and NT-proBNP increased compared to control subjects (apelin: 0.47±0.2 vs. 0.97±0.3ng/mL, p<0.001; NT-proBNP: 2007±114 vs. 229±72pmol/L, p<0.001). Short-term evaluation did not reveal any effect of CRT on apelin or NT-proBNP levels. By contrast, at 9±2months follow-up, CRT responders showed left ventricular reverse remodelling and an increase in ejection fraction, together with a significant increase in plasma apelin levels (0.99±0.1 vs. 0.47±0.2ng/mL, p<0.001) and decrease in NT-proBNP (938±591 vs. 2007±114pmol/L, p<0.05). Conclusions: Long-term CRT increases plasma levels of the endogenous inotrope apelin in patients with CHF.

3 August 2012 in Expert Opinion on Emerging Drugs
Verified
Journal Article
Closed access
LLLuana Lionetto
Luana Lionetto
ANAndrea Negro
Andrea Negro
SPStefano Palmisani
Stefano Palmisani
GGGiovanna Gentile
Giovanna Gentile
MFMaria Rosaria Del Fiore
Maria Rosaria Del Fiore
PMPaolo Martelletti
Paolo Martelletti
Introduction: Chronic migraine (CM), the suffering of 15 or more headache days with at least 8 of these migraine days, afflicts 1.3% - 5.1% of the global population. CM is the most common disorder faced by experts in tertiary headache centers. When resistant to conventional medical treatment and prophylactic medication this condition is known as refractory chronic migraine (RCM). RCM is one of the greatest challenges in headache medicine. Areas covered: State-of-the-art and future medical treatments of chronic migraine include: OnabotulinumtoxinA, antiepileptic drugs (Levetiracetam, Magnesium valproate hydrate, Lacosamide, BGG-492), 5-HT agonists (Lasmiditan, NXN-188, novel delivery systems of Sumatriptan, a well-established drug treatment for acute migraine), CGRP receptor antagonists (BMS-927711), ML-1 agonists (Ramelteon), orexin receptor antagonist (MK-6096), plant-derived compound (LLL-2011) and other multitarget drugs such as Tezampanel, Tonabersat, intranasal carbon dioxide and BOL-148. The role for neuromodulation, the application of targeted electrical stimulation, will be examined. Expert opinion: Medication overuse headache (MOH) is now recognized to be a major factor in many cases of both chronic and refractory chronic migraine. MOH must be addressed prior to evaluating the effectiveness of new preventative and prophylactic treatment approaches. Innovative new drugs and electrical neuromodulation are promising CM treatments. Future studies must carefully screen patients and acquire data that can lead to personalized, tailored treatment strategies.

1 October 2012
Verified
Journal Article
Closed access
Gianluca SerafiniGianluca Serafini
Gianluca Serafini
Maurizio PompiliMaurizio Pompili
Maurizio Pompili
Marco InnamoratiMarco Innamorati
Marco Innamorati
GGGiovanna Gentile
Giovanna Gentile
MBMarina Borro
Marina Borro
PMP. Martelleti
P. Martelleti

14 September 2009 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
LMLudovica Marcellini
Ludovica Marcellini
MBMarina Borro
Marina Borro
GGGiovanna Gentile
Giovanna Gentile
Andrea RinaldiAndrea Rinaldi
Andrea Rinaldi
Lorenzo StellaLorenzo Stella
Lorenzo Stella
Maria Luisa MangoniMaria Luisa Mangoni
Maria Luisa Mangoni
Antimicrobial peptides constitute one of the main classes of molecular weapons deployed by the innate immune system of all multicellular organisms to resist microbial invasion. A good proportion of all antimicrobial peptides currently known, numbering hundreds of molecules, have been isolated from frog skin. Nevertheless, very little is known about the effect(s) and the mode(s) of action of amphibian antimicrobial peptides on intact bacteria, especially when they are used at subinhibitory concentrations and under conditions closer to those encountered in vivo. Here we show that esculentin-1b(1–18) [Esc(1–18)] (GIFSKLAGKKLKNLLISG-NH2), a linear peptide encompassing the first 18 residues of the full-length esculentin-1b, rapidly kills Escherichia coli at the minimal inhibitory concentration. The lethal event is concomitant with the permeation of the outer and inner bacterial membranes. This is in contrast to what is found for many host defense peptides, which do not destabilize membranes at their minimal inhibitory concentrations. Importantly, proteomic analysis revealed that Esc(1–18) has a limited ability to modify the bacterium’s protein expression profile, at either bactericidal or sublethal concentrations. To the best of our knowledge, this is the first report on the effects of an antimicrobial peptide from frog skin on the proteome of its bacterial target, and underscores the fact that the bacterial membrane is the major target for the killing mechanism of Esc(1–18), rather than intracellular processes.

28 July 2015 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
GGGiovanna Gentile
Giovanna Gentile
ABAndrea Botticelli
Andrea Botticelli
LLL Lionetto
L Lionetto
FMF Mazzuca
F Mazzuca
MSM Simmaco
M Simmaco
MBMarina Borro
Marina Borro